Javascript Required
Your browser must have Javascript enabled in order for our dynamic player to be embedded. Please turn on Javascript in your browser preferences and then refresh this page.
 

Related Videos (12) - hide

Related Networks

Related Organizations

Premiere:
Septal Myectomy Surgery to Treat Obstructive Hypertrophic Cardiomyopathy (HCM)

Septal myectomy surgery to treat obstructive hypertrophic cardiomyopathy (HCM) is a complex cardiac surgical procedure that very few hospitals in the United States, and the world, have the expertise to perform. St. Luke’s Hospital in New York City is one of those hospitals, and the only one on the east coast that has performed a large volume of successful septal myectomy surgeries, providing a lifetime of relief for their patients suffering from severe symptoms of obstructive HCM.

Watch Daniel Swistel, MD, cardiac surgeon and surgical director of the Hypertrophic Cardiomyopathy Program at St. Luke’s and Roosevelt Hospitals, perform a septal myectomy surgery to treat severe obstructive hypertrophic cardiomyopathy. Dr. Swistel is internationally renowned for his expertise in performing HCM surgery, and has one of the largest operative experiences of active surgeons for the septal myectomy procedure. In addition, Dr. Swistel has introduced mitral valve repair techniques performed during the procedure that have greatly improved long-term patient outcomes.

Dr. Sandhya Balaram, interim chief of cardiac surgery at
St. Luke’s and also experienced in septal myectomy surgery, will be the assisting surgeon. 

About Obstructive Hypertrophic Cardiomyopathy (HCM)

Obstructive HCM is a condition where a thickening of the septum, or wall, between the left and right ventricles (lower chambers of the heart), often in combination with abnormal contact with the mitral valve, impedes the normal and complete flow of blood out of the heart and into the aorta.

Hypertrophic cardiomyopathy affects patients in different ways, with different symptoms and different levels of severity. Patients may have shortness of breath, exercise intolerance, chest pressure or pain, fainting, heart palpitations, or no symptoms at all. In unusual cases, HCM can cause sudden cardiac death. Every year, a few athletes at the high school, college and professional level, who have no prior symptoms, succumb to sudden death caused by HCM.

HCM occurs for no apparent clinical cause, and the condition is often inherited. Hypertrophic cardiomyopathy that is non-obstructive can be managed with medications, and in some cases, with an implantable cardioverter defibrillator, or ICD.

Patients often live with symptoms of obstructive hypertrophic cardiomyopathy for years as adults, but when the symptoms no longer respond to medications or other therapies, surgery is often the best course of action to correct the condition.

If you have been diagnosed with hypertrophic cardiomyopathy and seek treatment, including surgical options, please make an appointment with Dr. Mark Sherrid, Director of the HCM Program or Dr. Bette Kim at St. Luke’s-Roosevelt Hospital Center at 212.492.5570 or 212.492.5550. 

Roosevelt Hospital
Division of Cardiology
425 West 59th St., 9C
New York, NY 10019

St. Luke’s Hospital
1111 Amsterdam Avenue
Division of Cardiothoracic Surgery
Muhlenburg 2, Suite A
New York, NY 10025

Participants

Featuring:

Daniel Swistel

Daniel Swistel, MD

Surgical Director, Hypertrophic Cardiomyopathy Program,
St. Luke’s and Roosevelt Hospitals

Sandhya Balaram

Sandhya Balaram, MD, PhD

Interim Chief of Cardiac Surgery, St. Luke’s and Roosevelt Hospitals